Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT01325428
- Locations
- 🇹🇳
1200.89.21601 Boehringer Ingelheim Investigational Site, Ariana, Tunisia
🇺🇸1200.89.10005 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States
🇦🇺1200.89.61002 Boehringer Ingelheim Investigational Site, East Bentleigh, Victoria, Australia
Monotherapy Dose Finding With BI 847325 in Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: day 1 to day 14Drug: day 1 to day 5
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 69
- Registration Number
- NCT01324830
- Locations
- 🇧🇪
1287.1.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1287.1.3202 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
- Conditions
- Neoplasms
- Interventions
- Drug: BI 836845
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT01317420
- Locations
- 🇬🇧
1280.2.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1280.2.4402 Boehringer Ingelheim Investigational Site, Leeds, United Kingdom
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2089
- Registration Number
- NCT01316419
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 51, Jeju, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 54, Chonbuk, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 55, Busan, Korea, Republic of
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 465
- Registration Number
- NCT01316380
- Locations
- 🇦🇷
205.442.54003 Boehringer Ingelheim Investigational Site, Florencio Varela, Argentina
🇬🇹205.442.50203 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala
🇦🇷205.442.54002 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01316341
- Locations
- 🇨🇳
1245.44.86001 Boehringer Ingelheim Investigational Site, Beijing, China
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
- Conditions
- Ovarian NeoplasmsPeritoneal Neoplasms
- Interventions
- Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*minDrug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01314105
- Locations
- 🇪🇸
1199.119.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸1199.119.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸1199.119.34003 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 206
- Registration Number
- NCT01311661
- Locations
- 🇩🇪
1222.29.49006 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇸1222.29.11012 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
🇭🇺1222.29.36003 Boehringer Ingelheim Investigational Site, Nyiregyhaza, Hungary
Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01309139
- Locations
- 🇩🇪
1298.2.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
SMS Reminder to Assess Adherence
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: SMS reminderProcedure: control group
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 95
- Registration Number
- NCT01308476
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 3, Hamburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 1, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site 5, Lübeck, Germany